Nilo Therapeutics launched with a $101 million Series A led by The Column Group, DCVC Bio, and Lux Capital, joined by the Gates Foundation and Alexandria Venture Investments, and named Kim Seth, Ph.D., as CEO. The financing moves the company out of stealth to build New York–based labs and advance preclinical programs aimed at centrally regulating systemic inflammation via neural circuits.
The company’s thesis is to modulate immune activity by targeting brain–vagus pathways identified in academic work from founders at Columbia, Yale, and Harvard, rather than suppressing downstream cytokines in the periphery. Nilo positions its candidates as drugs, not devices, that engage central “master regulator” circuits to coordinate multiple immune pathways at once. The leadership bench blends translational immunology and drug discovery experience under Chief Scientific Officer Laurens Kruidenier, Ph.D., with company-building and deal-making depth from Seth, who helped scale Repare Therapeutics from inception through IPO.
Strategically, this is a clear bid to step around the crowded landscape of anti-TNF, IL-17/23, JAK, and TYK2 programs by moving upstream in the neuro-immune axis. It also attempts to capture the multi-pathway benefits seen in bioelectronic vagus nerve stimulation trials while keeping the convenience and scalability of pharmacology. The upside is breadth: a central control point could dampen inflammatory tone across indications without the cycling of resistance that can accompany single-cytokine blockade. The trade-off is translational risk. Establishing causal, druggable nodes within CNS–autonomic circuits, delivering molecules with appropriate CNS exposure, and preserving specificity to avoid autonomic or neuropsychiatric liabilities will be the defining execution challenges.
For sponsors and CROs, a centrally acting immunomodulator reshapes early clinical development. Proof-of-mechanism will likely hinge on integrated biomarker suites that tie central engagement to peripheral immune readouts: autonomic measures, neuroimaging or electrophysiology, alongside cytokine panels and acute inflammatory challenges. CROs with dual neuroscience–immunology capabilities and real-time biomarker operations will be advantaged. Research sites should anticipate cross-specialty study teams spanning neurology, rheumatology, and gastroenterology, with enhanced safety monitoring for CNS and cardiovascular effects. Regulators have been increasingly receptive to mechanism-driven biomarker strategies in early phase studies, but a CNS-acting therapy for autoimmune disease will require especially clear exposure–response, reversibility, and safety gating before expansion into broad indications. Vendors developing assays for autonomic tone, central target engagement, and multiplex inflammatory profiling are positioned to plug into these programs.
The financing scale suggests Nilo can run multiple IND-enabling tracks in parallel, but the near-term signal to watch is modality disclosure and first-indication selection. Choices like rheumatoid arthritisarthritis, IBD, or psoriasis offer established endpoints and competitive benchmarks; rarer inflammatory syndromes may provide faster PoM at the cost of commercial clarity. Expect early human studies to emphasize biomarker-rich designs—potentially including endotoxin challenge or vaccine-response models—to link central target engagement with systemic immune modulation before moving into patient cohorts. Key risks include off-target CNS effects, variability in neural circuit architecture across patients, and the operational complexity of integrating neuromodulatory biomarkers into routine autoimmune trial workflows. With a CEO oriented toward partnerships, external validation—through device-combo studies, pharma alliances, or shared biomarker platforms—may arrive before late-stage commitments. If Nilo can demonstrate reproducible central control of inflammatory tone with an acceptable safety margin, it will not only open a new competitive lane in immunology but also force incumbents to consider central-peripheral combination strategies. If not, this becomes another reminder that the neuro-immune junction is scientifically compelling but clinically unforgiving.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
